Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (9): 2571-2573.doi: 10.4103/NRR.NRR-D-24-00553

Previous Articles     Next Articles

Spinal cord injury regenerative therapy development: integration of design of experiments

Yuji Okano, Hideyuki Okano, Yoshitaka Kase*   

  1. Division of CNS Regeneration and Drug Discovery, International Center for Brain Science (ICBS), Fujita Health University, Kutsukake-Cho, Toyoake-Shi, Aichi, Japan (Okano Y, Okano H, Kase Y) Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Shinanomachi, Shinjuku-Ku, Tokyo, Japan (Okano Y) Keio University Regenerative Medicine Research Center, Kawasaki-ku, Kawasaki-shi, Japan (Okano H, Kase Y)
  • Online:2025-09-15 Published:2024-12-28
  • Contact: Yoshitaka Kase, MD, PhD, k.yoshitaka.med@keio.jp.
  • Supported by:
    We are grateful to Dr. Hans Dijkstra (Fujita Health University, Japan) for the critical reading of the manuscript. This work was supported by the Keio University Medical Science Fund (to YO), the General Insurance Association of Japan (to YK), the Takeda Science Foundation (to YK), and grants from the Japan Agency for Medical Research and Development (AMED) (Grant JP24bm1123037 and JP24ym0126118) (to HO).

PDF

71

Abstract: Spinal cord injury (SCI) can cause motor and sensory paralysis, and autonomic nervous system disorders including malfunction of urination and defecation, thereby significantly impairing the quality of life. Researchers continue to explore new stem cell strategies for the treatment of paralysis by transplanting human induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSCNS/PCs) into spinal cord injured tissues.